227 related articles for article (PubMed ID: 34841437)
1. ELOVL2 promotes cancer progression by inhibiting cell apoptosis in renal cell carcinoma.
Tanaka K; Kandori S; Sakka S; Nitta S; Tanuma K; Shiga M; Nagumo Y; Negoro H; Kojima T; Mathis BJ; Shimazui T; Watanabe M; Sato TA; Miyamoto T; Matsuzaka T; Shimano H; Nishiyama H
Oncol Rep; 2022 Feb; 47(2):. PubMed ID: 34841437
[TBL] [Abstract][Full Text] [Related]
2. ELOVL5-mediated fatty acid elongation promotes cellular proliferation and invasion in renal cell carcinoma.
Nitta S; Kandori S; Tanaka K; Sakka S; Siga M; Nagumo Y; Negoro H; Kojima T; Mathis BJ; Shimazui T; Miyamoto T; Matsuzaka T; Shimano H; Nishiyama H
Cancer Sci; 2022 Aug; 113(8):2738-2752. PubMed ID: 35670054
[TBL] [Abstract][Full Text] [Related]
3. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
[TBL] [Abstract][Full Text] [Related]
4. E2F1 promotes proliferation and metastasis of clear cell renal cell carcinoma via activation of SREBP1-dependent fatty acid biosynthesis.
Shen D; Gao Y; Huang Q; Xuan Y; Yao Y; Gu L; Huang Y; Zhang Y; Li P; Fan Y; Tang L; Du S; Wu S; Wang H; Wang C; Gong H; Pang Y; Ma X; Wang B; Zhang X
Cancer Lett; 2021 Aug; 514():48-62. PubMed ID: 34019961
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of CLDN7 due to promoter hypermethylation is associated with human clear cell renal cell carcinoma progression and poor prognosis.
Li Y; Gong Y; Ning X; Peng D; Liu L; He S; Gong K; Zhang C; Li X; Zhou L
J Exp Clin Cancer Res; 2018 Nov; 37(1):276. PubMed ID: 30428910
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological and survival analysis of clinically advanced papillary and chromophobe renal cell carcinoma.
Kaldany A; Paulucci DJ; Kannappan M; Beksac AT; Anastos H; Okhawere K; Sfakianos JP; Badani KK
Urol Oncol; 2019 Oct; 37(10):727-734. PubMed ID: 31174958
[TBL] [Abstract][Full Text] [Related]
7. CRISPR/Cas9-mediated ablation of elovl2 in Atlantic salmon (Salmo salar L.) inhibits elongation of polyunsaturated fatty acids and induces Srebp-1 and target genes.
Datsomor AK; Zic N; Li K; Olsen RE; Jin Y; Vik JO; Edvardsen RB; Grammes F; Wargelius A; Winge P
Sci Rep; 2019 May; 9(1):7533. PubMed ID: 31101849
[TBL] [Abstract][Full Text] [Related]
8. A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy.
Büttner FA; Winter S; Stühler V; Rausch S; Hennenlotter J; Füssel S; Zastrow S; Meinhardt M; Toma M; Jerónimo C; Henrique R; Miranda-Gonçalves V; Kröger N; Ribback S; Hartmann A; Agaimy A; Stöhr C; Polifka I; Fend F; Scharpf M; Comperat E; Wasinger G; Moch H; Stenzl A; Gerlinger M; Bedke J; Schwab M; Schaeffeler E
Genome Med; 2022 Sep; 14(1):105. PubMed ID: 36109798
[TBL] [Abstract][Full Text] [Related]
9. Sphingosine kinase 1 regulates lipid metabolism to promote progression of kidney renal clear cell carcinoma.
Zhao L; Wang Z; Xu Y; Zhang P; Qiu J; Nie D; Wu G; Chen C; Chang Y; Xia Q
Pathol Res Pract; 2023 Aug; 248():154641. PubMed ID: 37467634
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of the long noncoding RNA TUG1 inhibits the proliferation, migration, invasion and promotes apoptosis of renal cell carcinoma.
Zhang M; Lu W; Huang Y; Shi J; Wu X; Zhang X; Jiang R; Cai Z; Wu S
J Mol Histol; 2016 Aug; 47(4):421-8. PubMed ID: 27323757
[TBL] [Abstract][Full Text] [Related]
11. Free-Fatty Acid Receptor-4 (FFA4/GPR120) differentially regulates migration, invasion, proliferation and tumor growth of papillary renal cell carcinoma cells.
Karmokar PF; Moniri NH
Biochem Pharmacol; 2023 Jul; 213():115590. PubMed ID: 37201877
[TBL] [Abstract][Full Text] [Related]
12. Circulating and tissue IMP3 levels are correlated with poor survival in renal cell carcinoma.
Tschirdewahn S; Panic A; Püllen L; Harke NN; Hadaschik B; Riesz P; Horváth A; Szalontai J; Nyirády P; Baba HA; Reis H; Szarvas T
Int J Cancer; 2019 Jul; 145(2):531-539. PubMed ID: 30650187
[TBL] [Abstract][Full Text] [Related]
13. A pan-kidney cancer study identifies subtype specific perturbations on pathways with potential drivers in renal cell carcinoma.
Zhan X; Liu Y; Yu CY; Wang TF; Zhang J; Ni D; Huang K
BMC Med Genomics; 2020 Dec; 13(Suppl 11):190. PubMed ID: 33371886
[TBL] [Abstract][Full Text] [Related]
14. HADHA overexpression disrupts lipid metabolism and inhibits tumor growth in clear cell renal cell carcinoma.
Liu S; Liu X; Wu F; Zhang X; Zhang H; Gao D; Bi D; Qu H; Ge J; Xu Y; Zhao Z
Exp Cell Res; 2019 Nov; 384(1):111558. PubMed ID: 31472118
[TBL] [Abstract][Full Text] [Related]
15. The knockdown of the mediator complex subunit MED30 suppresses the proliferation and migration of renal cell carcinoma cells.
Syring I; Weiten R; Müller T; Schmidt D; Steiner S; Müller SC; Kristiansen G; Ellinger J
Ann Diagn Pathol; 2018 Jun; 34():18-26. PubMed ID: 29661722
[TBL] [Abstract][Full Text] [Related]
16. Expression and clinical value of SALL4 in renal cell carcinomas.
Che J; Wu P; Wang G; Yao X; Zheng J; Guo C
Mol Med Rep; 2020 Aug; 22(2):819-827. PubMed ID: 32468053
[TBL] [Abstract][Full Text] [Related]
17. MYCN and PRC1 cooperatively repress docosahexaenoic acid synthesis in neuroblastoma via ELOVL2.
Ding Y; Yang J; Ma Y; Yao T; Chen X; Ge S; Wang L; Fan X
J Exp Clin Cancer Res; 2019 Dec; 38(1):498. PubMed ID: 31856871
[TBL] [Abstract][Full Text] [Related]
18. YBX1 knockdown induces renal cell carcinoma cell apoptosis via Kindlin-2.
Cui Q; Wang C; Liu S; Du R; Tian S; Chen R; Geng H; Subramanian S; Niu Y; Wang Y; Yue D
Cell Cycle; 2021 Nov; 20(22):2413-2427. PubMed ID: 34709966
[TBL] [Abstract][Full Text] [Related]
19. The clinical utility of miR-21 as a diagnostic and prognostic marker for renal cell carcinoma.
Faragalla H; Youssef YM; Scorilas A; Khalil B; White NM; Mejia-Guerrero S; Khella H; Jewett MA; Evans A; Lichner Z; Bjarnason G; Sugar L; Attalah MI; Yousef GM
J Mol Diagn; 2012 Jul; 14(4):385-92. PubMed ID: 22580180
[TBL] [Abstract][Full Text] [Related]
20. Versican Promotes Tumor Progression, Metastasis and Predicts Poor Prognosis in Renal Carcinoma.
Mitsui Y; Shiina H; Kato T; Maekawa S; Hashimoto Y; Shiina M; Imai-Sumida M; Kulkarni P; Dasgupta P; Wong RK; Hiraki M; Arichi N; Fukuhara S; Yamamura S; Majid S; Saini S; Deng G; Dahiya R; Nakajima K; Tanaka Y
Mol Cancer Res; 2017 Jul; 15(7):884-895. PubMed ID: 28242813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
